Differences in tolerability of two commercial anagrelide formulations may be caused by differences in bioavailability
- PE Petrides (Author)
- H Gisslinger (Author)
- M Steurer (Author)
- Werner Linkesch (Author)
- G Krumpl (Author)
- A Schuller (Author)
- R Widmann (Author)
Activity: Talk, presentation or poster › Poster